Where Anti-Nucleocapsid (Anti-N) antibodies is reported
Also listed as: Infection-specific marker
| Condition | Direction | Compared against | Associated symptoms | Source |
|---|---|---|---|---|
| PACVS | ↓ reduced | Expected absent in vaccinated-only | Rules out prior SARS-CoV-2 infection | Federico 2024 |
Frequently asked questions
In which conditions is Anti-Nucleocapsid (Anti-N) antibodies altered?
In the OSMF atlas Anti-Nucleocapsid (Anti-N) antibodies is reported in PACVS. It is reduced in 1 across 1 entries.
Is there a standard clinical test for Anti-Nucleocapsid (Anti-N) antibodies?
The atlas entries for Anti-Nucleocapsid (Anti-N) antibodies do not carry a LOINC code, which usually means the marker was measured with research assays or study-specific methods rather than a routine clinical panel.
Is one abnormal Anti-Nucleocapsid (Anti-N) antibodies result diagnostic?
No single biomarker result is diagnostic of any of these conditions. Findings reflect group averages from published cohorts with substantial overlap between patients and controls.
Cite this page
Subscribe on Substack
Last reviewed: 2026-06-30 · Browse: Biomarker Index · All marker pages · Biomarker Atlas
Disclaimer: Educational synthesis of peer-reviewed research; not medical advice. Findings are group-level and vary with study design. Discuss any result with a qualified clinician.